Optimum dose of olsalazine for maintaining remission in ulcerative colitis.
نویسندگان
چکیده
منابع مشابه
Optimum dose of olsalazine for maintaining remission in ulcerative colitis
To evaluate the optimum dose of olsalazine for maintaining remission in ulcerative colitis, 198 patients in remission for more than three months were randomly assigned to receive 0.5 g, 1.0 g, or 2.0 g/day for 12 months. A dose-ranging effect was detected in the per protocol analysis, with remission rates of 60% (0.5 g), 70% (1.0 g), and 78% (2.0 g) (p=0.03, trend in proportions). The higher do...
متن کاملOptimum dose of olsalazine for maintaining remission in ulcerative colitis.
To evaluate the optimum dose of olsalazine for maintaining remission in ulcerative colitis, 198 patients in remission for more than three months were randomly assigned to receive 0.5 g, 1.0 g, or 2.0 g/day for 12 months. A dose-ranging effect was detected in the per protocol analysis, with remission rates of 60% (0.5 g), 70% (1.0 g), and 78% (2.0 g) (p = 0.03, trend in proportions). The higher ...
متن کاملInfluence of olsalazine on gastrointestinal transit in ulcerative colitis.
The effect of olsalazine on stool output and the transit of a solid radiolabelled meal through the stomach, small intestine and colon was studied in six patients with ulcerative colitis intolerant of sulphasalazine. Olsalazine 250 mg four times daily significantly accelerated gastric emptying (mean +/- SD; 45.3 +/- 24.2 min v 67.3 +/- 33.1 min, p less than 0.05), mouth to caecum transit time (2...
متن کاملReview article: defining remission in ulcerative colitis.
BACKGROUND There is no international agreement on scoring systems used to measure disease activity in ulcerative colitis, nor is there a validated definition for disease remission. AIM To review the principles and components for defining remission in ulcerative colitis and propose a definition that will help improve patient outcomes. METHODS A review of current standards of remission from t...
متن کاملMaintaining remission in ulcerative colitis – role of once daily extended-release mesalamine
The aminosalicylates (5-ASA; also referred to as mesalamine-based agents) are considered as first-line in the maintenance of remission of mild to moderate ulcerative colitis (UC). Traditionally these agents have required a large pill burden and multiple daily dosing regimens which may account for the low adherence rates, especially in patients in remission. Extended-release mesalamine is the fi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Gut
سال: 1994
ISSN: 0017-5749
DOI: 10.1136/gut.35.9.1282